Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eureka Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Porton Advanced, Eureka Collaborate to Accelerate T-Cell Therapy
Details : The collaboration aims to leverage proprietary ARTEMIS cell receptor and E‑ALPHA antibody discovery platforms to drive innovation in safer, more effective T‑cell therapies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 19, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eureka Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
KEY PRODUCTS
Reset All
Porton Pharma Solutions: Value creation via innovation & discovery through technical platforms.
